Skip to main content

27-10-2023 | Cancer of Unknown Primary | Expert Interview | Article | F. Hoffmann-La Roche Ltd.

Cancer of Unknown Primary: Key results from ESMO 2023


medwireNews is an independent medical news service provided by Springer Healthcare Ltd.

CUPISCO trial approach extends progression-free survival for CUP patients

CUPISCO trial investigator Prof. Linda Mileshkin describes the progression-free survival benefit achieved with use of molecularly guided treatment versus standard chemotherapy for patients with cancer of unknown primary.

Presentation date: Saturday 21st October 2023


  • Prof. Linda Mileshkin
    Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

ARCAGEN matches targeted treatment to almost half of rare tumor types

Dr. Marie Morfouace and Prof. Jean-Yves Blay discuss initial ARCAGEN study findings showing that almost half of patients with cancers of unknown primary and other rare tumors can be matched to a molecularly targeted therapy.

Presentation date: Sunday 22nd October 2023


  • Dr. Marie Morfouace
    EORTC, Brussels, Belgium
  • Prof. Jean-Yves Blay
    Centre Léon Bérard, Lyon, France

CUP-ONE supports gene expression assay for cancer of unknown primary 

Watch Dr. Harpreet Wasan explain the benefits of a joint gene expression and immunohistochemistry approach to identifying cancer of unknown primary origin.

Presentation date: Sunday 22nd October 2023


  • Dr. Harpreet Wasan
    Imperial College London, UK

Gene expression-directed chemotherapy improves CUP patient survival

Phase 3 trial findings show that a 90-gene expression assay can aid choice of chemotherapy and improve survival for patients with cancer of unknown primary.

Presentation date: Sunday 22nd October 2023


  • Prof. Zhiguo Luo 
    Fudan University Shanghai Cancer Center, China

Financial disclosure

This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.


Any information provided and opinions expressed do not necessarily reflect the views of Springer Medizin GmbH. Springer Medizin GmbH and its employees, agents and subcontractors are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Please consult the latest prescribing information from the manufacturer before issuing prescriptions for any products mentioned.

Related topics

Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare